A new era of cystic fibrosis therapy with CFTR modulators.
作者信息
Barros Laura Gomes Boabaid de, Prestes Laura Menestrino, Fernandes Maria Fernanda Gonçalves Meirelles, Silva-Filho Luiz Vicente Ribeiro Ferreira da, Pinto Leonardo Araújo
机构信息
. Grupo de Pesquisa em Epidemiologia e Genética das Doenças Respiratórias da Infância, Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS - Porto Alegre (RS) Brasil.
. Instituto da Criança e do Adolescente, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.
出版信息
J Bras Pneumol. 2025 Jan 20;50(6):e20240405. doi: 10.36416/1806-3756/e20240405.
Abstract
摘要
相似文献
1
A new era of cystic fibrosis therapy with CFTR modulators.使用CFTR调节剂治疗囊性纤维化的新时代。
J Bras Pneumol. 2025 Jan 20;50(6):e20240405. doi: 10.36416/1806-3756/e20240405.
2
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.囊性纤维化 CFTR 变异体特异性治疗（包括调节剂）的护理标准。
J Cyst Fibros. 2023 Jan;22(1):17-30. doi: 10.1016/j.jcf.2022.10.002. Epub 2022 Oct 28.
3
Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.不适合当前 CFTR 调节剂的囊性纤维化患者的治疗方法。
Cells. 2021 Oct 19;10(10):2793. doi: 10.3390/cells10102793.
4
Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis.接受囊性纤维化跨膜传导调节因子调节剂治疗的囊性纤维化患者肝硬化发病率降低。
World J Hepatol. 2022 Feb 27;14(2):411-419. doi: 10.4254/wjh.v14.i2.411.
5
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.在 CFTR 调节剂时代重新审视囊性纤维化肺部的宿主-病原体相互作用。
Int J Mol Sci. 2023 Mar 5;24(5):5010. doi: 10.3390/ijms24055010.
6
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of Pharmacology and Clinical Translation.新型囊性纤维化跨膜传导调节因子调节剂作为囊性纤维化的新药：药理学与临床转化概述
ACS Pharmacol Transl Sci. 2019 Oct 2;3(1):4-10. doi: 10.1021/acsptsci.9b00060. eCollection 2020 Feb 14.
7
Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.囊性纤维化跨膜电导调节因子（CFTR）调节剂时代的囊性纤维化肝病。
Paediatr Respir Rev. 2024 Jun;50:54-61. doi: 10.1016/j.prrv.2023.12.005. Epub 2023 Dec 28.
8
A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.一个令人担忧的问题：调节剂时代囊性纤维化患者胃肠道症状的调查
NIHR Open Res. 2024 Feb 5;3:18. doi: 10.3310/nihropenres.13384.1. eCollection 2023.
9
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.理解并满足囊性纤维化患者在 CFTR 调节剂治疗时代的需求。
Lancet Respir Med. 2023 Oct;11(10):916-931. doi: 10.1016/S2213-2600(23)00324-7. Epub 2023 Sep 9.
10
Emerging medicines to improve the basic defect in cystic fibrosis.新兴药物改善囊性纤维化的基本缺陷。
Expert Opin Emerg Drugs. 2022 Sep;27(3):229-239. doi: 10.1080/14728214.2022.2092612. Epub 2022 Jul 1.
本文引用的文献
1
Cystic fibrosis.囊性纤维化。
Nat Rev Dis Primers. 2024 Aug 8;10(1):53. doi: 10.1038/s41572-024-00538-6.
2
Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.使用 elexacaftor+tezacaftor+ivacaftor 治疗至少携带一个 F508del 等位基因的囊性纤维化个体：系统评价和荟萃分析。
J Bras Pneumol. 2024 Jan 5;49(6):e20230187. doi: 10.36416/1806-3756/e20230187. eCollection 2024.
3
Cystic Fibrosis: A Review.囊性纤维化：综述。
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
4
Worldwide rates of diagnosis and effective treatment for cystic fibrosis.全球囊性纤维化的诊断和有效治疗率。
J Cyst Fibros. 2022 May;21(3):456-462. doi: 10.1016/j.jcf.2022.01.009. Epub 2022 Feb 4.
Zotero 插件